Tumor necrosis factor inhibitors in psoriasis: an update.

Abstract

Three inhibitors of tumor necrosis factor (TNF) currently are approved for the treatment of psoriasis: etanercept, infliximab, and adalimumab. The other two TNF inhibitors, golimumab and certolizumab pegol, have shown efficacy against plaque psoriasis in clinical trials of psoriatic arthritis (PsA). This article reviews the most recent evidence on the efficacy and safety of the TNF inhibitors in psoriasis, with special attention to preventing and managing immunogenicity.

• Authors: Francisco A Kerdel, Bruce E Strober
• Journal: Seminars in cutaneous medicine and surgery (Semin Cutan Med Surg) Vol. 33 Issue 2 Suppl 2 Pg. S31-6 (Mar 2014) ISSN: 1085-5629 [Print] United States
• PMID: 24979543 (Publication Type: Journal Article)
• Copyright: 2014 published by Frontline Medical Communications.

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Humanized
• Immunoglobulin Fab Fragments
• Immunoglobulin G
• Receptors, Tumor Necrosis Factor
• Tumor Necrosis Factor Inhibitors
• Polyethylene Glycols
• golimumab
• Infliximab
• Adalimumab
• Etanercept
• Certolizumab Pegol

Topics

• Adalimumab
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Humanized (therapeutic use)
• Certolizumab Pegol
• Etanercept
• Humans
• Immunoglobulin Fab Fragments (therapeutic use)
• Immunoglobulin G (therapeutic use)
• Infliximab
• Polyethylene Glycols (therapeutic use)
• Psoriasis (drug therapy)
• Receptors, Tumor Necrosis Factor (therapeutic use)
• Tumor Necrosis Factor Inhibitors